Verona Pharma plc Verona Pharma Plc: Grant Of Options To Pdmr

 
TIDMVRP 
 
   LONDON, Nov. 27, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) 
(Nasdaq:VRNA) ("Verona Pharma"), a biopharmaceutical company focused on 
respiratory diseases, announces that, on November 26, 2019, it granted 
500,000 options to purchase ordinary shares of GBP0.05 each (the 
"Ordinary Shares") to its CEO, Dr. Jan-Anders Karlsson, under and in 
accordance with Verona Pharma's 2017 Incentive Award Plan (which is set 
out in Verona Pharma's 2018 annual report and 20-F) (the "Options"). 
 
   The Options have an exercise price of GBP0.445 per Ordinary Share, being 
the closing mid-market price on November 25, 2019. The Options will vest 
over two different periods following the grant date:  250,000 of the 
options will vest in three substantially equal annual instalments and 
the other half of the Options will vest in four substantially equal 
annual instalments. 
 
   Further information is provided below in accordance with the 
requirements of the EU Market Abuse Regulation. 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                       Tel: +44 (0)20 3283 4200 
Jan-Anders Karlsson, Chief Executive    mailto:info@veronapharma.com 
Officer                                 info@veronapharma.com 
                                        -------------------------------------- 
Victoria Stewart, Director of 
Communications 
 
N+1 Singer                              Tel: +44 (0)20 3283 4200 
 (Nominated Adviser and UK Broker) 
Aubrey Powell 
Mia Gardner (Corporate Broking) 
 
 
   Notification and public disclosure of transactions by persons 
discharging managerial responsibilities and persons closely associated 
with them. 
 
 
 
 
1     Details of the person discharging managerial responsibilities 
       / person closely associated 
 
a)    Name                        Dr. Jan-Anders Karlsson 
 
2     Reason for the notification 
 
a)    Position/status             Chief Executive Officer 
 
b)    Initial notification        Initial Notification 
      /Amendment 
 
3     Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
 
a)    Name                        Verona Pharma plc 
 
b)    Legal Entity Identifier     213800EVI6O6J3TIAL06 
 
4     Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place 
       where transactions have been conducted 
 
a)    Description of the          Ordinary shares of 5p each 
      financial instrument, 
      type of instrument 
 
      Identification code         ISIN Code: GB00BYW2KH80 
 
b)    Nature of the               Issue of options over Ordinary Shares 
      transaction 
 
c)    Price(s) and volume(s) 
                                  --------------------  -------------------- 
                                  Price(s)                Volume(s) 
 
                                  Exercise Price:         500,000 Options 
                                  GBP0.445                over Ordinary 
                                                          Shares 
 
 
d)    - Aggregated information    N/a (single transaction) 
       - Aggregated volume 
       - Price 
 
e)    Date of the transaction     26 November 2019 
 
f)    Place of the transaction    Off market

(END) Dow Jones Newswires

November 27, 2019 02:00 ET (07:00 GMT)

Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024